ENOV earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -1.33. Updated 2026-07-23.
Enovis (ENOV) Research Hub
Enovis (ENOV) trades on NYSE, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 19.28 USD (+1.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.33, market cap 1.52B. This hub links to the full technical, earnings and options research available for ENOV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NYSE, US |
| Last close | 19.28 USD (+1.31%) |
| 52-week range | 18.08 USD – 31.67 USD |
| Trend regime | Range |
| 14-day RSI | 27.5 (Oversold) |
| Trailing P/E | -1.33 |
| Market cap | 1.52B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ENOV
Covered Call on ENOV: how it works, illustrative setup around the real 19.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENOV: how it works, illustrative setup around the real 19.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENOV: how it works, illustrative setup around the real 19.28 USD price, max profit/loss, breakeven and when to use it. Educational.
ENOV technical analysis: range, last 19.28 USD, RSI 27.5, 52w range 18.08 USD–31.67 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENOV in?
Enovis (ENOV) is classified under Healthcare (Medical - Devices), listed on NYSE, US.
Is ENOV in an uptrend or downtrend?
As of 2026-09-11, ENOV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENOV's trailing P/E ratio?
ENOV's trailing P/E is -1.33, with a market cap of 1.52B. See the earnings research page for full valuation detail.
When does ENOV next report earnings?
ENOV is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 0.83 USD.